drugset / Trial / NCT06743126
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Timeline
- Start
- 2025-01-14
- Primary completion
- 2028-01
- Completion
- 2031-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Dacarbazine | Small molecule | — | — |
| Subject | IMA203 | Cell therapy | — | — |
| Comparator | Ipilimumab | Monoclonal antibody | — | — |
| Comparator | Nivolumab | Monoclonal antibody | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Comparator | Relatlimab | Monoclonal antibody | — | — |
| Comparator | Temozolomide | Small molecule | — | — |
| Comparator | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |